Tedizolid phosphate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314248

CAS#: 856867-55-5 (phosphate)

Description: Tedizolid phosphate, also know as TR-701FA tedizolid, torezolid (trade name Sivextro), is an oxazolidinone drug being developed by Cubist Pharmaceuticals following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Tedizolid has been approved by the FDA on June 20, 2014, for the treatment of MRSA skin infections.

Chemical Structure

Tedizolid phosphate
CAS# 856867-55-5 (phosphate)

Theoretical Analysis

MedKoo Cat#: 314248
Name: Tedizolid phosphate
CAS#: 856867-55-5 (phosphate)
Chemical Formula: C17H16FN6O6P
Exact Mass: 450.0853
Molecular Weight: 450.32
Elemental Analysis: C, 45.34; H, 3.58; F, 4.22; N, 18.66; O, 21.32; P, 6.88

Price and Availability

Size Price Availability Quantity
100.0mg USD 150.0 Same day
200.0mg USD 250.0 Same day
500.0mg USD 450.0 Same day
1.0g USD 850.0 Same day
2.0g USD 1250.0 Same day
5.0g USD 1950.0 Same day
10.0g USD 2850.0 2 Weeks
20.0g USD 3950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 856867-39-5 (disodium)   856867-55-5 (phosphate)   856866-72-3    

Synonym: TR701-FA; TR-701-FA; TR 701-FA; torezolid; tedizolid phosphate; trade name Sivextro.

IUPAC/Chemical Name: (R)-(3-(3-fluoro-4-(6-(2-methyl-2H-tetrazol-5-yl)pyridin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl dihydrogen phosphate


InChi Code: InChI=1S/C17H16FN6O6P/c1-23-21-16(20-22-23)15-5-2-10(7-19-15)13-4-3-11(6-14(13)18)24-8-12(30-17(24)25)9-29-31(26,27)28/h2-7,12H,8-9H2,1H3,(H2,26,27,28)/t12-/m1/s1

SMILES Code: O=C1O[C@@H](COP(O)(O)=O)CN1C2=CC=C(C3=CC=C(C4=NN(C)N=N4)N=C3)C(F)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 450.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gras J. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783. PubMed PMID: 25525633.

2: Sahm DF, Deane J, Bien PA, Locke JB, Zuill DE, Shaw KJ, Bartizal KF. Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe. Diagn Microbiol Infect Dis. 2015 Feb;81(2):112-8. doi: 10.1016/j.diagmicrobio.2014.08.011. Epub 2014 Aug 30. PubMed PMID: 25488274.

3: Cada DJ, Ingram K, Baker DE. Tedizolid phosphate. Hosp Pharm. 2014 Nov;49(10):961-71. doi: 10.1310/hpj4910-961. PubMed PMID: 25477569; PubMed Central PMCID: PMC4252220.

4: Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, Prokocimer P. Analysis of the Phase 3 ESTABLISH Trials of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2015 Feb;59(2):864-71. doi: 10.1128/AAC.03688-14. Epub 2014 Nov 24. PubMed PMID: 25421472.

5: Jones RN, Holliday NM, Rhomberg PR. Validation of a commercial dry-form broth microdilution device (sensititre) for testing tedizolid, a new oxazolidinone. J Clin Microbiol. 2015 Feb;53(2):657-9. doi: 10.1128/JCM.02769-14. Epub 2014 Nov 19. PubMed PMID: 25411167.

6: Schlosser MJ, Hosako H, Radovsky A, Butt MT, Draganov D, Vija J, Oleson F. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months. Antimicrob Agents Chemother. 2015 Jan;59(1):475-81. doi: 10.1128/AAC.03950-14. Epub 2014 Nov 10. PubMed PMID: 25385101; PubMed Central PMCID: PMC4291389.

7: Hussar DA, Nguyen A. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab. J Am Pharm Assoc (2003). 2014 Nov-Dec;54(6):658-62. doi: 10.1331/JAPhA.2014.14543. PubMed PMID: 25379985.

8: Flanagan S, McKee EE, Das D, Tulkens PM, Hosako H, Fiedler-Kelly J, Passarell J, Radovsky A, Prokocimer P. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015 Jan;59(1):178-85. doi: 10.1128/AAC.03684-14. Epub 2014 Oct 20. PubMed PMID: 25331703; PubMed Central PMCID: PMC4291347.

9: Rybak JM, Marx K, Martin CA. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Pharmacotherapy. 2014 Nov;34(11):1198-208. doi: 10.1002/phar.1491. Epub 2014 Sep 30. PubMed PMID: 25266820.

10: Lodise TP, Fang E, Minassian SL, Prokocimer PG. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198-204. doi: 10.1128/AAC.03509-14. Epub 2014 Sep 22. PubMed PMID: 25246392; PubMed Central PMCID: PMC4249542.

11: Zurenko G, Bien P, Bensaci M, Patel HN, Thorne G. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone. Ann Clin Microbiol Antimicrob. 2014 Sep 20;13:46. doi: 10.1186/s12941-014-0046-0. PubMed PMID: 25238753; PubMed Central PMCID: PMC4291835.

12: Wong E, Rab S. Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections. P T. 2014 Aug;39(8):555-79. PubMed PMID: 25136252; PubMed Central PMCID: PMC4123804.

13: Flanagan S, Passarell J, Lu Q, Fiedler-Kelly J, Ludwig E, Prokocimer P. Tedizolid population pharmacokinetics, exposure response, and target attainment. Antimicrob Agents Chemother. 2014 Nov;58(11):6462-70. doi: 10.1128/AAC.03423-14. Epub 2014 Aug 18. PubMed PMID: 25136028; PubMed Central PMCID: PMC4249359.

14: Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob Agents Chemother. 2014 Nov;58(11):6471-6. doi: 10.1128/AAC.03431-14. Epub 2014 Aug 18. PubMed PMID: 25136024; PubMed Central PMCID: PMC4249404.

15: Chen H, Yang Q, Zhang R, He W, Ma X, Zhang J, Xia F, Zhao F, Cao J, Liu Y, Wu W, Hu D, Wang Q, Zhao C, Zhang F, Wang X, Wang Z, Li H, Wang H. In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China. Int J Antimicrob Agents. 2014 Sep;44(3):276-7. doi: 10.1016/j.ijantimicag.2014.05.007. Epub 2014 Jun 23. PubMed PMID: 25108879.

16: Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy. 2014 Sep;34(9):891-900. doi: 10.1002/phar.1458. Epub 2014 Jul 3. PubMed PMID: 24989138; PubMed Central PMCID: PMC4260119.

17: Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5. PubMed PMID: 24909499.

18: Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, Prokocimer P. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. Drug Metab Dispos. 2014 Aug;42(8):1275-84. doi: 10.1124/dmd.113.056697. Epub 2014 May 29. PubMed PMID: 24875463.

19: Molina-Torres CA, Barba-Marines A, Valles-Guerra O, Ocampo-Candiani J, Cavazos-Rocha N, Pucci MJ, Castro-Garza J, Vera-Cabrera L. Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages. Ann Clin Microbiol Antimicrob. 2014 Apr 4;13:13. doi: 10.1186/1476-0711-13-13. PubMed PMID: 24708819; PubMed Central PMCID: PMC3986449.

20: Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm. 2014 Apr 15;71(8):621-33. doi: 10.2146/ajhp130482. Review. PubMed PMID: 24688035.